Latest Pain Therapeutics (PTIE) Headlines
77.2% Return Seen to Date on SmarTrend Pain Therapeutics Call (PTIE)
Comtex SmarTrend(R) - Mon Mar 10, 9:08AM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ
TIE) on August 19th, 2013 at $3.05. In approximately 7 months, Pain Therapeutics has returned 77.16% as of today's recent price of $5.39.
Pain Therapeutics Invited to Present at 26th Annual ROTH Conference
GlobeNewswire - Thu Mar 06, 8:24AM CST
Pain Therapeutics, Inc. (Nasdaq TIE) today announced that Remi Barbier, Chairman, President & CEO, will present at ROTH Capital Partners' 26th Annual ROTH Conference on Monday, March 10 at 12:30 p.m. Pacific Time at the Ritz-Carlton, Laguna Niguel in Dana Point, California.
Pain Therapeutics (PTIE) Enters Overbought Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:40AM CST
Pain Therapeutics (PTIE) Enters Overbought Territory
Shares of PTIE Up 85.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 28, 4:42PM CST
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ TIE) on August 19th, 2013 at $3.05. In approximately 6 months, Pain Therapeutics has returned 85.55% as of today's recent price of $5.65.
Pain Therapeutics Invited to Present at Cowen Health Care Conference in Boston
GlobeNewswire - Tue Feb 25, 9:25AM CST
Pain Therapeutics, Inc. (Nasdaq TIE) today announced that Remi Barbier, Chairman, President & CEO, will present at Cowen and Company's 34 Annual Health Care Conference on Monday, March 3 at 3:30 p.m. Eastern Time at the Copley Place Hotel.
Pain Therapeutics Earnings Hindsight: Up 35.2% in Last 20 Days (PTIE)
Comtex SmarTrend(R) - Mon Feb 24, 7:18AM CST
When Pain Therapeutics (NASDAQ TIE) reported earnings two weeks ago on February 4th, 2014, analysts, on average, expected the company to report a loss of $0.01 on sales of $2.0 million. The company actually reported EPS of $0.72 on sales of $35.2 million, beating EPS estimates by $0.73 and beating revenue estimates by $33.2 million. Since the company's report, shares of Pain Therapeutics have risen from $3.92 to $5.30, representing a gain of 35.2% in the past 20 days.
Concise Analysis of the International Pain Management Therapeutics Market - Forecasts to 2018
M2 - Mon Feb 24, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tdvkjn/pain_management) has announced the addition of the "Concise Analysis of the International Pain Management Therapeutics Market - Forecasts to 2018" report to their offering. This report studies the global market for pain management therapeutics from three perspectives - therapeutic classes of drugs, indications and geography. Each of these segments is further classified into sub-segments; therapeutic classes include anticonvulsants, antidepressants, anesthetics, NSAIDs, opioids, anti-migraine agents and other non-narcotic analgesics. The various pain management indications studied in this report include neuropathic pain, fibromyalgia, arthritic pain, chronic back pain, migraine, post-operative pain and cancer pain. Market sizes and forecasts for the period 2010 - 2018 have been provided for each of the segments and sub-segments in terms of USD million, considering 2011 as the base year. The % compound annual growth rate (CAGR) for each market segment for the forecast period (2012 to 2018) has been provided along with market size estimations. Geographically, the market has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The respective market sizes and forecasts have been provided for each of these regions along with the CAGR. The market overview section of the report provides a detailed breakdown of various aspects of market dynamics such as drivers, restraints and opportunities along with market attractiveness analysis and Porter's five force analysis for the pain management therapeutics market. The competitive landscape section includes market share analysis of all the leading players in the branded pharmaceuticals market for pain management, in terms of percentage share in the year 2011. Key Topics Covered: 1 Preface 2 Executive Summary 3 Market Overview 4 Global Pain Management Therapeutics Market, by Therapeutic Class 5 Global Pain Management Therapeutics Market, by Indication 6 Global Pain Management Therapeutics Market, by Geography 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - Abbott Laboratories - Allergan - Covidien - Durect Corporation - Eli Lilly and Company - Endo Health Solutions - Forest Laboratories - GlaxoSmithKline - Hospira - Johnson & Johnson - Merck & Co - Mundipharma International - Novartis International - NuPathe - Pain Therapeutics - Pfizer - Purdue Pharma - QRx Pharma - Sanofi - Teva Pharmaceutical Industries - UCB (Union Chemnique Belge) For more information visit http://www.researchandmarkets.com/research/td...management
Pain Therapeutics Has Returned 77.3% Since SmarTrend Recommendation (PTIE)
Comtex SmarTrend(R) - Fri Feb 21, 10:59AM CST
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ TIE) on August 19th, 2013 at $3.05. In approximately 6 months, Pain Therapeutics has returned 77.34% as of today's recent price of $5.40.
Pain Therapeutics Shares Up 65.2% Since SmarTrend's Buy Recommendation (PTIE)
Comtex SmarTrend(R) - Fri Feb 14, 9:37AM CST
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ TIE) on August 19th, 2013 at $3.05. In approximately 6 months, Pain Therapeutics has returned 65.19% as of today's recent price of $5.03.
This Is America's Fastest-Growing Drug Problem
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 09, 1:15PM CST
There are few wars that the United States can conceivably say it's not won, but the war on illicit drugs and general drug abuse continues to be one such instance where there's no clear victory in sight. According to a National Drug Threat Survey ...
Strength Seen in Pain Therapeutics Inc. (PTIE) Stock Surges 24% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 7:44AM CST
Pain Therapeutics Inc. was a big mover last session, as the company saw its shares surge over 21% on the day.
Stock to Watch: Pain Therapeutics Up 10.5% (PTIE)
Comtex SmarTrend(R) - Wed Feb 05, 12:46PM CST
Pain Therapeutics (NASDAQ TIE) is one of today's best performing low-priced stocks, up 10.5% to $4.33 on 1.1x average daily volume. Pain Therapeutics has traded 453,000 shares thus far today, vs. average volume of 401,000 shares per day. The stock has outperformed the Dow (10.5% to the Dow's 0.1%) and outperformed the S&P 500 (10.5% to the S&P's -0.0%) during today's trading.
Research and Markets: Concise Analysis of the International Pain Therapeutics Market - Updated 2014 Report
Business Wire - Wed Feb 05, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/mzdfcp/pain_therapeutics) has announced the addition of a new report "Concise Analysis of the International Pain Therapeutics Market - Updated 2014 Report" to their offering.
Concise Analysis of the International Pain Therapeutics Market - Updated 2014 Report
M2 - Wed Feb 05, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/ffxbpd/pain_therapeutics) has announced the addition of a new report "Concise Analysis of the International Pain Therapeutics Market - Updated 2014 Report" to their offering. "Concise Analysis of the International Pain Therapeutics Market - Updated 2014 Report", describes the latest concepts of pathomechanisms of pain as a basis for management and development of new pharmacotherapies for pain. Major segments of the pain market are arthritis, neuropathic pain and cancer pain. Because pain is a subjective sensation, it is difficult to evaluate objectively in clinical trials. Various tools for pain measurement are described, including brain imaging. Most of the currently used analgesic drugs fall into the categories of opioids and nonsteroidal antiinflammatory drugs such as COX-2 inhibitors. Non-opioid analgesics include ketamine, a N-methyl-D-aspartate receptor antagonist. Adjuvant analgesics include antidepressants and antiepileptic drugs used for the treatment of neuropathic pain. Management of pain is multidisciplinary and includes both pharmacological and non-pharmacological methods such as acupuncture, transcutaneous electrical nerve stimulation and surgery. Various pain syndromes require different approaches in management, for example, the main category of drugs for migraine are triptans such as sumatriptan. Over 500 companies have been identified to be involved in developing or marketing pain therapeutics and 169 of these are profiled in the report along with 148 collaborations. These are a mix of pharmaceutical companies and biotechnology companies. The worldwide analgesic markets were analyzed for the year 2013 and projected to 2023. Calculations are based on the epidemiology of various painful conditions and the development of analgesic drugs and devices. Unfulfilled needs for analgesics are identified and strategies are outlined to develop markets for analgesic drugs. Key Topics Covered: Executive Summary 1. Basic Aspects of Pain 2. Assessment of Pain and Analgesics 3. Pharmacotherapy of Pain 4. Management of Pain 5. Drug Delivery for Pain 6. Drug Development for Pain 7. Legal and regulatory issues of pain management 8. Pain Markets 9. Future of Pain Therapeutics 10. Companies Involved in Pain Therapeutics 11. References For more information visit http://www.researchandmarkets.com/research/ff...erapeutics
Pain Therapeutics Reports 2013 Financial Results and Provides Guidance for 2014
GlobeNewswire - Tue Feb 04, 9:48PM CST
Pain Therapeutics, Inc. (Nasdaq TIE) today reported financial results for 2013 and provided guidance for 2014. Net profit in 2013 was $31.5 million, or $0.70 per diluted share, compared to a net loss in 2012 of $3.4 million, or $0.08 per share.
Can Nektar Therapeutics Beat Pfizer Inc.?
Cory Renauer, The Motley Fool - Motley Fool - Tue Feb 04, 9:55AM CST
The development of effective medications for the management of chronic pain has been difficult for many pharma companies. Pfizer and Pain Therapeutics have gotten close with tamper resistant versions of Oxycodone. Nektar Therapeutics ,...
Pain Therapeutics to Host Year-End Conference Call on February 4, 2014
GlobeNewswire - Wed Jan 29, 5:08PM CST
Pain Therapeutics, Inc. (Nasdaq TIE) will host a conference call on Tuesday, February 4, 2014 at 4:00 p.m. Central Time/5:00 p.m. Eastern Time to discuss year-end 2013 financial results, provide an update on the Company and respond to questions.
Agenda Released for Pain Therapeutics 2014
PRWeb - Fri Jan 17, 11:31AM CST
Pain Therapeutics 2014 will evaluate the translational gap on pain indications and issues faced with generic incursion and patent expiration.
Pain Therapeutics - Drugs, Markets and Companies
PR Newswire Europe - Thu Jan 16, 1:01PM CST
Research and Markets ( http://www.researchandmarkets.com/research/sq...rapeutics) has announced the addition of a new report "Pain Therapeutics - Drugs, Markets and Companies" [http://www.researchandmarkets.com/research/sqmftt/pain_therapeutics ] to their offering.
77.2% Return Seen to Date on SmarTrend Pain Therapeutics Call (PTIE)
Comtex SmarTrend(R) - Mon Mar 10, 9:08AM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ
TIE) on August 19th, 2013 at $3.05. In approximately 7 months, Pain Therapeutics has returned 77.16% as of today's recent price of $5.39. Pain Therapeutics Invited to Present at 26th Annual ROTH Conference
GlobeNewswire - Thu Mar 06, 8:24AM CST
Pain Therapeutics, Inc. (Nasdaq
TIE) today announced that Remi Barbier, Chairman, President & CEO, will present at ROTH Capital Partners' 26th Annual ROTH Conference on Monday, March 10 at 12:30 p.m. Pacific Time at the Ritz-Carlton, Laguna Niguel in Dana Point, California. Pain Therapeutics (PTIE) Enters Overbought Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:40AM CST
Pain Therapeutics (PTIE) Enters Overbought Territory
Shares of PTIE Up 85.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 28, 4:42PM CST
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ
TIE) on August 19th, 2013 at $3.05. In approximately 6 months, Pain Therapeutics has returned 85.55% as of today's recent price of $5.65. Pain Therapeutics Invited to Present at Cowen Health Care Conference in Boston
GlobeNewswire - Tue Feb 25, 9:25AM CST
Pain Therapeutics, Inc. (Nasdaq
TIE) today announced that Remi Barbier, Chairman, President & CEO, will present at Cowen and Company's 34 Annual Health Care Conference on Monday, March 3 at 3:30 p.m. Eastern Time at the Copley Place Hotel. Pain Therapeutics Earnings Hindsight: Up 35.2% in Last 20 Days (PTIE)
Comtex SmarTrend(R) - Mon Feb 24, 7:18AM CST
When Pain Therapeutics (NASDAQ
TIE) reported earnings two weeks ago on February 4th, 2014, analysts, on average, expected the company to report a loss of $0.01 on sales of $2.0 million. The company actually reported EPS of $0.72 on sales of $35.2 million, beating EPS estimates by $0.73 and beating revenue estimates by $33.2 million. Since the company's report, shares of Pain Therapeutics have risen from $3.92 to $5.30, representing a gain of 35.2% in the past 20 days. Concise Analysis of the International Pain Management Therapeutics Market - Forecasts to 2018
M2 - Mon Feb 24, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tdvkjn/pain_management) has announced the addition of the "Concise Analysis of the International Pain Management Therapeutics Market - Forecasts to 2018" report to their offering. This report studies the global market for pain management therapeutics from three perspectives - therapeutic classes of drugs, indications and geography. Each of these segments is further classified into sub-segments; therapeutic classes include anticonvulsants, antidepressants, anesthetics, NSAIDs, opioids, anti-migraine agents and other non-narcotic analgesics. The various pain management indications studied in this report include neuropathic pain, fibromyalgia, arthritic pain, chronic back pain, migraine, post-operative pain and cancer pain. Market sizes and forecasts for the period 2010 - 2018 have been provided for each of the segments and sub-segments in terms of USD million, considering 2011 as the base year. The % compound annual growth rate (CAGR) for each market segment for the forecast period (2012 to 2018) has been provided along with market size estimations. Geographically, the market has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The respective market sizes and forecasts have been provided for each of these regions along with the CAGR. The market overview section of the report provides a detailed breakdown of various aspects of market dynamics such as drivers, restraints and opportunities along with market attractiveness analysis and Porter's five force analysis for the pain management therapeutics market. The competitive landscape section includes market share analysis of all the leading players in the branded pharmaceuticals market for pain management, in terms of percentage share in the year 2011. Key Topics Covered: 1 Preface 2 Executive Summary 3 Market Overview 4 Global Pain Management Therapeutics Market, by Therapeutic Class 5 Global Pain Management Therapeutics Market, by Indication 6 Global Pain Management Therapeutics Market, by Geography 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - Abbott Laboratories - Allergan - Covidien - Durect Corporation - Eli Lilly and Company - Endo Health Solutions - Forest Laboratories - GlaxoSmithKline - Hospira - Johnson & Johnson - Merck & Co - Mundipharma International - Novartis International - NuPathe - Pain Therapeutics - Pfizer - Purdue Pharma - QRx Pharma - Sanofi - Teva Pharmaceutical Industries - UCB (Union Chemnique Belge) For more information visit http://www.researchandmarkets.com/research/td...management
Pain Therapeutics Has Returned 77.3% Since SmarTrend Recommendation (PTIE)
Comtex SmarTrend(R) - Fri Feb 21, 10:59AM CST
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ
TIE) on August 19th, 2013 at $3.05. In approximately 6 months, Pain Therapeutics has returned 77.34% as of today's recent price of $5.40. Pain Therapeutics Shares Up 65.2% Since SmarTrend's Buy Recommendation (PTIE)
Comtex SmarTrend(R) - Fri Feb 14, 9:37AM CST
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ
TIE) on August 19th, 2013 at $3.05. In approximately 6 months, Pain Therapeutics has returned 65.19% as of today's recent price of $5.03. This Is America's Fastest-Growing Drug Problem
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 09, 1:15PM CST
There are few wars that the United States can conceivably say it's not won, but the war on illicit drugs and general drug abuse continues to be one such instance where there's no clear victory in sight. According to a National Drug Threat Survey ...
Strength Seen in Pain Therapeutics Inc. (PTIE) Stock Surges 24% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 7:44AM CST
Pain Therapeutics Inc. was a big mover last session, as the company saw its shares surge over 21% on the day.
Stock to Watch: Pain Therapeutics Up 10.5% (PTIE)
Comtex SmarTrend(R) - Wed Feb 05, 12:46PM CST
Pain Therapeutics (NASDAQ
TIE) is one of today's best performing low-priced stocks, up 10.5% to $4.33 on 1.1x average daily volume. Pain Therapeutics has traded 453,000 shares thus far today, vs. average volume of 401,000 shares per day. The stock has outperformed the Dow (10.5% to the Dow's 0.1%) and outperformed the S&P 500 (10.5% to the S&P's -0.0%) during today's trading. Research and Markets: Concise Analysis of the International Pain Therapeutics Market - Updated 2014 Report
Business Wire - Wed Feb 05, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/mzdfcp/pain_therapeutics) has announced the addition of a new report "Concise Analysis of the International Pain Therapeutics Market - Updated 2014 Report" to their offering.
Concise Analysis of the International Pain Therapeutics Market - Updated 2014 Report
M2 - Wed Feb 05, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/ffxbpd/pain_therapeutics) has announced the addition of a new report "Concise Analysis of the International Pain Therapeutics Market - Updated 2014 Report" to their offering. "Concise Analysis of the International Pain Therapeutics Market - Updated 2014 Report", describes the latest concepts of pathomechanisms of pain as a basis for management and development of new pharmacotherapies for pain. Major segments of the pain market are arthritis, neuropathic pain and cancer pain. Because pain is a subjective sensation, it is difficult to evaluate objectively in clinical trials. Various tools for pain measurement are described, including brain imaging. Most of the currently used analgesic drugs fall into the categories of opioids and nonsteroidal antiinflammatory drugs such as COX-2 inhibitors. Non-opioid analgesics include ketamine, a N-methyl-D-aspartate receptor antagonist. Adjuvant analgesics include antidepressants and antiepileptic drugs used for the treatment of neuropathic pain. Management of pain is multidisciplinary and includes both pharmacological and non-pharmacological methods such as acupuncture, transcutaneous electrical nerve stimulation and surgery. Various pain syndromes require different approaches in management, for example, the main category of drugs for migraine are triptans such as sumatriptan. Over 500 companies have been identified to be involved in developing or marketing pain therapeutics and 169 of these are profiled in the report along with 148 collaborations. These are a mix of pharmaceutical companies and biotechnology companies. The worldwide analgesic markets were analyzed for the year 2013 and projected to 2023. Calculations are based on the epidemiology of various painful conditions and the development of analgesic drugs and devices. Unfulfilled needs for analgesics are identified and strategies are outlined to develop markets for analgesic drugs. Key Topics Covered: Executive Summary 1. Basic Aspects of Pain 2. Assessment of Pain and Analgesics 3. Pharmacotherapy of Pain 4. Management of Pain 5. Drug Delivery for Pain 6. Drug Development for Pain 7. Legal and regulatory issues of pain management 8. Pain Markets 9. Future of Pain Therapeutics 10. Companies Involved in Pain Therapeutics 11. References For more information visit http://www.researchandmarkets.com/research/ff...erapeutics
Pain Therapeutics Reports 2013 Financial Results and Provides Guidance for 2014
GlobeNewswire - Tue Feb 04, 9:48PM CST
Pain Therapeutics, Inc. (Nasdaq
TIE) today reported financial results for 2013 and provided guidance for 2014. Net profit in 2013 was $31.5 million, or $0.70 per diluted share, compared to a net loss in 2012 of $3.4 million, or $0.08 per share. Can Nektar Therapeutics Beat Pfizer Inc.?
Cory Renauer, The Motley Fool - Motley Fool - Tue Feb 04, 9:55AM CST
The development of effective medications for the management of chronic pain has been difficult for many pharma companies. Pfizer and Pain Therapeutics have gotten close with tamper resistant versions of Oxycodone. Nektar Therapeutics ,...
Pain Therapeutics to Host Year-End Conference Call on February 4, 2014
GlobeNewswire - Wed Jan 29, 5:08PM CST
Pain Therapeutics, Inc. (Nasdaq
TIE) will host a conference call on Tuesday, February 4, 2014 at 4:00 p.m. Central Time/5:00 p.m. Eastern Time to discuss year-end 2013 financial results, provide an update on the Company and respond to questions. Agenda Released for Pain Therapeutics 2014
PRWeb - Fri Jan 17, 11:31AM CST
Pain Therapeutics 2014 will evaluate the translational gap on pain indications and issues faced with generic incursion and patent expiration.
Pain Therapeutics - Drugs, Markets and Companies
PR Newswire Europe - Thu Jan 16, 1:01PM CST
Research and Markets ( http://www.researchandmarkets.com/research/sq...rapeutics) has announced the addition of a new report "Pain Therapeutics - Drugs, Markets and Companies" [http://www.researchandmarkets.com/research/sqmftt/pain_therapeutics ] to their offering.
